BDSI - addiction contract

Keep that in mind for six months from now when you're put on a plan or fired for low sales.

 

nice offer for me.... 90k, stock options, car allowance!

 

Oh yes absolutely, the same molecule is better than the other same molecule. That's great science.

 

The train is leaving. And you're not on it. Hmmm. Same molecule theory.... Wow, you may be onto something. I guess alternative DELIVERY methods don't matter. Efficacy and absorption are all the same.

I hope you didn't mention that in your interview.

I heard that Preparation H is hiring for their new products. It can be taken orally or the traditional suppository method. Same great taste

 

Quote from the head of sales:

We’ve had 4,300 candidates that applied for the position.
About 2,100 of those candidates met our qualifications, which were very difficult to get in as a matter of fact one of the things that they had to meet in order to be even interviewed by our field management team is they had to be in the top 10% ranking report of the other companies that they were working for or had worked for in the past.

they had a meeting with us at least six times before they got into the final interviews and we ended up with 56 of the top sales reps out of the 4,300.

So let’s talk a little about some demographics. Roughly 75% of this team came to us and they were already aligned to the target offices that we’re going to be calling on. They’re either in pain, they were in lab services and they’ve had pharma experience in the background before they were in lab services talking to the same offices and/or they were in the Addiction space already.

 

Bull crap!!!

 

So you are saying that 4300 of the TOP REPS in Pharma all applied for a contract position to sell a me to product to Drs and patients who are in love with Suboxone. Really??

 

Quintiles has set up a team of Super All-Stars to absolutely crush Suboxone. You just wait and see!

 

BAHAHA! You mean ex vivitrol reps ( how well did that product work out), ex Lab reps ( no Pharma code so anything goes) and pain mgt ( could sell off label to their buddies - major compliance no no) - Bring it on!

 

Good luck! Zubsolv has about 3% of the market after a year. This product is just another knock off. You can't go up against Suboxone reps, some of which have been in their territories for 10 years....the docs are loyal to them and pissed that insurance is forcing them from the Film. Oh, and RB is suing the pants off BDSI for patent infringement.

 

RB will buy BDSI when they spin off new business unit!

 

Thanks Kramer! I will invest every penny I have and buy BDSI stock!

 

Completely agree with this comment!!!

 

No stupid. That was all the applications received, including yours. They only looked at the top ones. I'm Guessing reading comprehension was a large component of their hiring criteria.

BTW, preparation H is hiring demonstrators, if your still looking for a job.

 

Reckitt Benckiser Group Plc (RB/) will spin off its pharmaceutical unit after concluding the business that once accounted for a fifth of earnings doesn’t fit into Chief Executive Officer Rakesh Kapoor’s plan to focus on consumer health.

The spinoff will occur in the next 12 months and will listed in the U.K. The division gets almost all of its 780 million pounds ($1.3 billion) of revenue from Suboxone.

Addiction treatment is not “a space we want to be in,” Kapoor has said as he reviewed the business after generic variants of the drug began to erode sales and margins.

The spinoff means “it hasn’t been able to attract a trade buyer on satisfactory terms,” James Edwardes Jones, an analyst at RBC Europe, said.

BUMMER. I'm guessing you are a lot smarter than the RB CEO. The writing is on the wall.

 

Sure is....you don't know the first thing about RB. They're an OTC and consumer products company. Suboxone didn't fit into their long-term strategy. They make and sell Lysol, French's Mustard, and Woolite for God's sake! The higher ups on the pharma side wanted out from under RB's umbrella and control, to focus on addictions treatment. We already have ADDICTION products coming down the pipeline. But you wouldn't know that bc you don't work here. Nice try, asshole.

 

RB addiction products in the pipeline? It's been almost 10 yrs !!!! They will sell off this unit to Pain related company...Purdue? Endo? Etc... Easy purchase for Big Pharma.. They will dump RB reps during the process...Suboxone sells itself now....hard work done years ago! It's over for the slackers, good reps will find work no problem...dust off those resumes "slackers"

 

You don't know what the fuck you're talking about. They aren't selling the company. They already announced the spinoff.

Nothing in the pipeline, eh?

A pharmacy professor at the University of Kentucky has developed a nasal spray of naloxone (Narcan) to treat potentially fatal overdoses from heroin and prescription opioids. Although naloxone injections are currently used by emergency workers to treat overdose cases, Daniel Wermeling, PharmD, believes nasally administered naloxone is quicker and more effective. "You can fill a prescription at one of our pharmacies and have this in your home if you have an at-risk family member," Dr. Wermeling told the Lexington Herald-Leader. Dr. Wermeling’s intranasal naloxone treatment has been in development since 2009 and is currently undergoing a final round of clinical trials. Because the drug recently received Fast Track designation from the FDA, it could be available to the public as early as next year, pending approval. "The goal is to make the medication available to patients at high risk of opioid overdose and to caregivers, including family members, who may lack specialized medical training," Dr. Wermeling noted. To develop intranasal naloxone, Dr. Wermeling’s company, AntiOp, collaborated with Reckitt Benckiser Pharmaceuticals, Inc, which has the option to acquire all rights to the product upon its FDA approval, according to a FierceDrugDelivery report. In a statement, Reckitt Benckiser CEO Shaun Thaxter said, "we view the FDA decision to grant Fast Track designation to AntiOp for intranasal naloxone as an exciting and positive first step toward accelerating the commercialization of a simple, ready-to-use treatment needed to address the growing epidemic of opioid overdose.” At a recent news conference, Dr. Wermeling honed in on the fact that tougher prescription drug laws have led to more addicts turning to heroin and other opioids. Because heroin is administered with needles, he speculated that the rate of HIV/AIDS will increase as a result of needle sharing. - See more at: http://www.pharmacytimes.com/product-news/Pharmacist-Develops-Naloxone-Nasal-Spray-to-Reverse-Drug-Overdoses#sthash.QuTguXWM.dpuf